NuCana plc (NASDAQ:NCNA) Short Interest Update

NuCana plc (NASDAQ:NCNA) saw a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 9,300 shares, a drop of 94.4% from the March 31st total of 164,900 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average daily volume of 70,700 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, Oppenheimer reissued an “outperform” rating and issued a $100.00 target price on shares of NuCana in a research note on Monday, April 1st.

NuCana Stock Performance

NuCana stock remained flat at $3.84 during trading hours on Thursday. The company’s stock had a trading volume of 16,490 shares, compared to its average volume of 58,149. The business’s 50 day moving average price is $7.02 and its 200-day moving average price is $8.85. The stock has a market capitalization of $8.03 million, a P/E ratio of -0.24 and a beta of 0.92. NuCana has a fifty-two week low of $3.40 and a fifty-two week high of $23.75.

NuCana (NASDAQ:NCNA) last released its earnings results on Wednesday, March 20th. The company reported ($4.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.25) by ($1.00). On average, equities research analysts predict that NuCana will post -12.06 earnings per share for the current year.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.